Results 161 to 170 of about 36,987 (240)

Multi‐Class Blood Cancer Malignancy Prediction From Microscopic Blood Cell Images Using ShuffleNetV2

open access: yesVector: The Journal of Engineering, Volume 2027, Issue 1, January/December 2027.
A lightweight ShuffleNetV2‐based deep learning model is proposed for multi‐class blood cancer classification using microscopic blood cell images. The model achieves 95.69% accuracy and 0.9979 AUC while maintaining low computational cost, demonstrating its suitability for efficient clinical diagnostic support in resource‐constrained environments ...
Muhammad Azam Rasheed   +7 more
wiley   +1 more source

Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke   +10 more
wiley   +1 more source

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin   +92 more
wiley   +1 more source

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair   +11 more
wiley   +1 more source

Clinically suspected central nervous system Richter transformation presenting with progressive psychiatric symptoms: A case report

open access: yesPsychiatry and Clinical Neurosciences Reports, Volume 5, Issue 4, December 2026.
Abstract Background Central nervous system (CNS) involvement associated with Richter transformation (RT) is a rare complication of chronic lymphocytic leukemia (CLL). Neurological manifestations are heterogeneous. To our knowledge, no previous reports have described CNS RT presenting predominantly with psychiatric and behavioral symptoms.
Tetsuro Ishida, Yusuke Sugama
wiley   +1 more source

Evolutionary trade‐offs between beauvericin production and growth define divergent virulence strategies in Beauveria

open access: yesPest Management Science, Volume 82, Issue 12, Page 10987-10998, December 2026.
Two virulence strategies in Beauveria: a growth strategy characterized by rapid within‐host proliferation, and a toxin strategy involving antimicrobial activity and toxicity to insects Abstract BACKGROUND Pathogen virulence is often attributed to toxin production, yet toxins are metabolically costly and may not universally enhance fitness.
Shasha Hu   +3 more
wiley   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 12, Page 1088-1096, December 2026.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan   +15 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1421-1441, December 2026.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

Safety of Lowering the Platelet Transfusion Threshold Before Central Venous Catheterisation in Patients With Haematological Diseases

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1531-1540, December 2026.
ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational before‐and‐after study including the first non‐tunnelled CVC insertion ...
Mathias Lazarevic Lindblad   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy